Anaphylaxis is an unpredictable, potentially fatal systemic allergic reaction requiring rapid recognition and immediate intervention. Despite robust international clinical practice guidelines, persistent misconceptions among healthcare providers and patients frequently result in delayed administration of first-line therapy. In real-world community and emergency settings, clinicians and caregivers continue to rely heavily on oral antihistamines and systemic corticosteroids, underutilizing epinephrine out of unfounded safety concerns.

In Module 1 of Managing Anaphylaxis in the Real World, hosted by Sarah Williams, MAT, two leading allergy and immunology specialists—Manish Ramesh, MD, PhD, Chief of the Division of Allergy and Immunology at Montefiore Medical Center and Associate Professor at Albert Einstein College of Medicine, and Anna Nowak-Węgrzyn, MD, PhD, Professor of Pediatrics at NYU Grossman School of Medicine and Director of the Pediatric Allergy and Immunology Division at Hassenfeld Children's Hospital—discuss the physiological mechanisms of anaphylaxis, critical diagnostic red flags in non-verbal children, and evidence-based management principles for the multidisciplinary care team.

Deconstructing the First-Line Role of Epinephrine vs Antihistamines

The session opened with an examination of a real-world pediatric case: a toddler, previously diagnosed with a cashew allergy, who presented with a facial rash after consuming hazelnut spread. Although an oral second-generation antihistamine (cetirizine) temporarily cleared the cutaneous hives, the systemic reaction continued to evolve inwardly into abdominal cramping, behavioral lethargy, vomiting, and a recurring rash that ultimately required urgent medical care and intramuscular epinephrine.

Dr. Nowak-Węgrzyn emphasized that cutaneous clearing following antihistamine administration frequently creates a false sense of security.

“Antihistamines act symptomatically. They will treat mild symptoms like rashes and itching; they block the receptors,” Dr. Nowak-Węgrzyn explained. “Even though the reaction may be ongoing, once you block those receptors, you don’t see mild symptoms, but your body is still working. This is in contrast to epinephrine, which if you use it really early, actually stops the reaction. It stabilizes the mast cells and stops the release of the additional mediators.”

Dr. Ramesh reinforced that oral antihistamines are strictly adjunctive and lack the pharmacodynamic capability to arrest systemic anaphylaxis.

“Oral antihistamines are useful in patients who are having very mild symptoms, like hives or itchy mouth, but they do not block all the pathways in anaphylaxis,” Dr. Ramesh stated. “Epinephrine, on the other hand, does work at multiple points in the anaphylaxis pathway. And for that reason, it is considered a first line.”

Recognizing Subtle Pediatric Presentations and Trusting Parental Intuition

Identifying anaphylaxis in young children poses unique diagnostic challenges because infants and toddlers cannot clearly verbalize physiological sensations such as pharyngeal edema, nausea, or presyncope. Instead, systemic progression often manifests as subtle behavioral alterations, such as sudden clinginess, becoming uncharacteristically withdrawn, crankiness, or profound fatigue.

When an allergic reaction is suspected, clinicians must educate parents to pay close attention to behavioral shifts following food ingestion. Dr. Nowak-Węgrzyn pointed out that an individualized, written Anaphylaxis Action Plan must be reviewed and updated at every clinical encounter, explicitly defining when to transition from symptomatic oral antihistamines to prompt epinephrine delivery.

Both experts stressed the importance of lowering the threshold to treat. “Parents know their children very well, and they can tell the difference between their normal sleepiness or crankiness and their not-so-normal sleepiness and crankiness,” Dr. Ramesh noted. “I often advise parents to lean on their intuition, and generally it's not wrong. The risk associated with using epinephrine even if you're wrong is low.”

Dr. Nowak-Węgrzyn agreed, underscoring a fundamental clinical rule: “When in doubt, use epinephrine. If something is not right, and you cannot really put your finger on it, use epinephrine.”

Dispelling Provider Misconceptions

A substantial portion of the discussion addressed deep-seated provider misconceptions that hinder optimal clinical management.

“There are a number of physicians who have misconceptions about epinephrine management as well,” Dr. Ramesh noted. “For many physicians, they continue to believe that antihistamines and steroids are the primary management of anaphylaxis, even though there are several studies and years of guidelines that have contradicted that it's epinephrine first, epinephrine fast.”

Dr. Ramesh clarified that systemic corticosteroids have no proven role in halting acute anaphylaxis or preventing biphasic reactions, cautioning against reflexive multi-day steroid tapers.

Provider hesitation is particularly pronounced in special populations, such as adults with cardiovascular comorbidities and pregnant individuals. Dr. Ramesh addressed the common clinical fear of epinephrine-induced cardiac ischemia: “People who have cardiac risk factors are often underdosed with epinephrine because there is a concern that they may have a cardiac issue because of using epinephrine. We like to emphasize that not using epinephrine or having inadequate treatment of anaphylaxis is more likely to cause a cardiac problem or myocardial infarction rather than using epinephrine.”

Similarly, pregnancy should never serve as a contraindication to epinephrine. The human myometrium contains high densities of mast cells; during anaphylaxis, massive mediator release can induce uterine hypertonicity, severe cramping, and spontaneous miscarriage. Maternal hypoxemia and distributive shock pose far-greater risks to fetal viability than the transient vasoconstrictive effects of therapeutic epinephrine.

Supportive Care and Home Monitoring Protocols

Beyond pharmacotherapy, proper patient positioning is a critical, life-saving maneuver that clinicians must emphasize to emergency personnel and caregivers. Dr. Ramesh highlighted the fatal risk of sudden postural changes: “Reclining the patient is quite important when someone's having anaphylaxis to maintain enough circulation back, enough preload to the heart and venous return, so that you don't have empty heart syndrome where you don't have enough blood flow coming through.”

Finally, the panel challenged the historical dogma that any administration of an epinephrine auto-injector automatically necessitates an emergency department transfer. If a patient experiences mild anaphylaxis, symptoms resolve completely and rapidly following a single dose of epinephrine, additional doses are readily available, and the family resides close to emergency medical facilities, careful home observation and subsequent outpatient allergist follow-up represent a safe, viable approach.

Key Takeaways

Epinephrine is the sole first-line therapy for anaphylaxis; it acts across multiple adrenergic receptors to stabilize mast cells, reverse vasodilation, and prevent fatal airway compromise.
Antihistamines provide symptomatic relief solely for mild cutaneous signs (pruritus, urticaria) and can mask systemic progression without stopping the underlying mediator cascade.
Systemic corticosteroids lack clinical trial evidence for acute anaphylaxis management and should not be routinely prescribed as multi-day discharge regimens.
In pediatric patients, sudden behavioral changes (lethargy, irritability, becoming withdrawn) following allergen ingestion may signify evolving systemic involvement and warrant immediate epinephrine.
Cardiovascular disease and pregnancy are not contraindications to full-dose epinephrine; hypoxia, hypotension, and anaphylaxis-induced mast cell activation carry substantially higher risks of myocardial infarction and fetal loss than epinephrine itself.
Recumbent patient positioning with elevated lower extremities is vital to preserve cardiac venous return, adequate preload, and prevent empty heart syndrome.
Mild anaphylactic reactions that resolve completely after a single epinephrine dose may be monitored at home in reliable settings with rapid access to secondary emergency care.

About the Speakers

Manish Ramesh, MD, PhD, is the Chief of the Division of Allergy and Immunology at Montefiore Medical Center and an Associate Professor of Allergy and Immunology at Albert Einstein College of Medicine. He specializes in the prevention and treatment of food allergies. Dr. Ramesh started the Food Allergy Center at Montefiore and developed an oral immunotherapy program for children and adults. He is passionate about improving care for patients with food allergies.

Anna Nowak-Wegrzyn, MD, PhD, is a Professor of Pediatrics at NYU Grossman School of Medicine and the Director of the Pediatric Allergy and Immunology Division at Hassenfeld Children's Hospital, NYU Langone Health. She specializes in the prevention and treatment of allergies in children. Dr. Nowak-Wegrzyn is passionate about helping patients navigate allergies and anaphylaxis from childhood into young adulthood. She also serves on the Board of Directors of the American Academy of Allergy, Asthma, and Immunology.

Managing Anaphylaxis in the Real World: Module 1 — Identifying and Treating Anaphylaxis